Assessment of Tumor Response in Mice with Ovarian Peritoneal Carcinomatosis using Doppler Ultrasound of the Superior Mesenteric Artery and Celiac Trunk

Ultrasound Med Biol. 2021 Mar;47(3):759-768. doi: 10.1016/j.ultrasmedbio.2020.11.030. Epub 2021 Jan 6.

Abstract

The goal of the work described here was to assess the performance of Doppler ultrasound (US) of the superior mesenteric artery (SMA) and celiac trunk (CT) in the evaluation of tumor response in female mice with ovarian peritoneal carcinomatosis treated either with bevacizumab or with carboplatin. Compared with untreated mice, carboplatin-treated mice had a lower weight (23.3 ± 2.0 vs. 27.9 ± 2.9 g, p < 0.001), peritoneal carcinomatosis index (PCI, 11 ± 3 vs. 28 ± 6, p < 0.001), Ki67-positive staining surfaces (p < 0.001), vascular density (p < 0.001), mean blood flow velocity (mBFVel) in the SMA (7.0 ± 1.4 vs. 10.9 ± 1.8 cm/s, p < 0.001) and CT (8.0 ± 1.8 vs. 14.3 ± 4.6 cm/s, p < 0.001) and no ascites. Weight and mBFVel were similar in bevacizumab-treated and untreated mice. The mBFVels in the SMA and CT correlated with the PCI used as an estimation of the tumor burden, R = 0.70 (p < 0.0001) and R = 0.65 (p < 0.0001), respectively. Doppler US allows non-invasive assessment of the effects of anticancer therapy in ovarian peritoneal carcinomatosis-induced mice.

Keywords: Celiac trunk; Doppler ultrasound; Ovarian peritoneal carcinomatosis; Peritoneal carcinomatosis; Superior mesenteric artery; Tumor response.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Carboplatin / therapeutic use*
  • Celiac Artery / diagnostic imaging*
  • Female
  • Mesenteric Artery, Superior / diagnostic imaging*
  • Mice
  • Mice, Inbred C57BL
  • Ovarian Neoplasms / blood supply*
  • Ovarian Neoplasms / drug therapy*
  • Peritoneal Neoplasms / blood supply*
  • Peritoneal Neoplasms / drug therapy*
  • Treatment Outcome
  • Tumor Cells, Cultured
  • Ultrasonography, Doppler*

Substances

  • Antineoplastic Agents
  • Bevacizumab
  • Carboplatin